Raymond James & Associates’s Strata Critical Medical Inc SRTA Stock Holding History

Raymond James & Associates’s Portfolio SRTA Stock Details SRTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.3M	Sell	440,635 -213,252	-33%	-$679K	﹤0.01%	2515
2024 Q2	$2.28M	Buy	653,887 +37,243	+6%	+$124K	﹤0.01%	2080
2024 Q1	$1.76M	Buy	616,644 +362,784	+143%	+$1.12M	﹤0.01%	2250
2023 Q4	$896K	Sell	253,860 -221,232	-47%	-$635K	﹤0.01%	2585
2023 Q3	$1.23M	Buy	+475,092	New	+$1.67M	﹤0.01%	2325
2022 Q1	–	Sell	-49,740	Closed	-$439K	–	4124
2021 Q4	$439K	Sell	49,740 -19,241	-28%	-$183K	﹤0.01%	3181
2021 Q3	$717K	Buy	68,981 +706	+1%	+$6.17K	﹤0.01%	2800
2021 Q2	$717K	Buy	68,275 +2,425	+4%	+$23.9K	﹤0.01%	2820
2021 Q1	$678K	Buy	65,850 +41,250	+168%	+$574K	﹤0.01%	2782
2020 Q4	$273K	Buy	+24,600	New	+$251K	﹤0.01%	3181

Other funds holding SRTA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Raymond James & Associates's SRTA Position: Q3 2024 in Review

Raymond James & Associates reduced its Strata Critical Medical Inc (SRTA) stake by 33% in Q3 2024, selling an estimated $679K and leaving 440,635 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2515.

Raymond James & Associates first reported a position in SRTA in Q4 2020 and has held it in 10 quarters since. The position peaked at $2.28M in Q2 2024. 120 funds tracked by Wall St. Rank hold SRTA as of Q3 2024.

Raymond James & Associates held 440,635 shares of Strata Critical Medical Inc worth $1.3M as of Q3 2024.
Raymond James & Associates sold 213,252 Strata Critical Medical Inc shares in Q3 2024, an estimated $679K.
Strata Critical Medical Inc made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2515 holding.
Raymond James & Associates first reported a position in Strata Critical Medical Inc in Q4 2020 and has held it in 10 quarters since.
Raymond James & Associates's Strata Critical Medical Inc position peaked at $2.28M in Q2 2024.
120 funds tracked by Wall St. Rank held Strata Critical Medical Inc as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.